Yan Leyfman
Jun 9, 2025, 07:12
Yan Leyfman: Are Immune Checkpoint Inhibitors Safe for Patients with Neurologic Autoimmune Disorders?
Yan Leyfman, Co-founder and Executive Director of MedNews Week, posted on X:
“Are Immune Checkpoint Inhibitors (ICIs) Safe for Patients with Neurologic Autoimmune Disorders (NAIDs)?
A multicenter study of 135 cancer patients with NAIDs sheds light:
- Myasthenia Gravis (MG): Highest risk — 67% had neurologic exacerbations, some severe or fatal.
- Multiple Sclerosis (MS): 18% experienced flares — generally milder.
- Guillain-Barré (GBS): No exacerbations observed, but 1 fatal immune-related event.
- Survival Outcomes: No difference in PFS or OS across NAID groups.
Takeaway: ICIs may be viable for many with NAIDs, but caution is crucial, especially in MG.”
More posts featuring Yan Leyfman on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 9, 2025, 05:26
Jun 9, 2025, 05:19
Jun 9, 2025, 04:15
Jun 9, 2025, 04:06
Jun 9, 2025, 03:59
Jun 9, 2025, 03:26
Jun 9, 2025, 03:08